KR101103393B1 - Composition containing a herbal extract for preventing and treating respiratory organ disease - Google Patents

Abstract

The present invention relates to a composition for the prophylaxis and treatment of respiratory diseases exhibiting antitussive and expectorant activity, and specifically, selected from the group consisting of one or more herbal extracts selected from the group consisting of baekbaek, chylopodium and ducts; It can be used as a pharmaceutical composition and health functional food useful for the prevention and treatment of respiratory diseases by containing two or more mixed herbal extracts as an active ingredient and confirming that it exhibits expectorant activity, antitussive activity and antihistamine activity.

Yellowish white, comedy, fellowship, respiratory organs, expectorant, Jinhae, antihistamine

Description

Composition containing a herbal extract for preventing and treating respiratory organ disease}

 The present invention relates to a composition useful for the prevention and treatment of respiratory diseases as an antitussive or expectorant composition containing as an active ingredient at least one extract selected from the group consisting of yellowish white, rare and yeongyo.

 In addition, the present invention relates to a composition for the prevention and treatment of respiratory diseases as an antitussive or expectorant composition containing as an active ingredient two or more mixed extracts selected from the group consisting of yellowish white, rare and ducts.

The respiratory system of our body is one of the organs that constantly defends against physical and chemical stimuli. When the stimulant enters the respiratory tract, most of the stimulant gets caught in the nose and does not enter the respiratory tract, but the fine stimulant passed through it is surrounded by mucus, The tiny cilia located on the airway wall send them out or up, which is the basic principle of coughing. Cough, as mentioned earlier, is a reflexive defense mechanism caused by airway mucosal stimulation, and when a persistent cough is caused by excessive stimulation, it reduces and worsens the quality of life of the patient. In the same principle as coughing, when dust or irritants are introduced from the outside, the body's bronchus moves muscles with saliva and pushes them to the outside. This is the cause of sputum formation, which causes dark purulent sputum due to inflammation of the bronchus and lungs. Will be.

      As a result, cough and sputum are caused by physical and chemical factors such as cold air, external foreign substances, including pathogenic microorganisms, air pollutants, and allergens, which can be divided into three categories.

      First, stimulation of cough receptors in the larynx, trachea, bronchus, pharynx, sinuses, diaphragm due to physical and chemical factors, the stimulus is transmitted to the cough center of the soft zone of the brain and cough reflex occurs. The mechanisms of antitussives, which are closely related to these irritant cough reflexes, are classified into central and peripheral, and the mechanisms of central antitussives are drugs that control cough by inhibiting the relieving center of soft water, such as codeine and dextromethorphan ( dextromethorphan, noscapine, ephedrine, zipeprol, etc. These components often cause side effects such as cardiovascular thrombosis, myocardial infarction, respiratory depression, sedation, and gastrointestinal disorders. There is. Peripheral antitussives act on the kidney's kidney receptor (stretch receptor) to control cough, which is relatively safe to compensate for the disadvantages of central antitussives, and the development of such antitussives has recently been tried a number of representative drugs Levopropizine, benzonatate, benzozaine, benzyl alcohol, and the like are used.

      Second, when the parasympathetic nervous system is activated due to physico-chemical factors, bronchial smooth muscle contracts and thus symptoms such as bronchial spasms and bronchial contractions may occur. At this time, the beta 2 agonist stimulates the beta 2 receptor to relax the smooth muscle, and the xanthine derivative increases cAMP or inhibits bronchial smooth muscle by inhibition of phosphodiesterase. It acts as a direct relaxation, increasing mucus secretion while dissolving mucus and promoting ciliary movement. Drugs exhibiting this action include beta 2 agonists such as clenbuterol, bambuterol and formoterol, and xanthine derivatives such as theophylline and aminophylline. aminophylline), acepiphylline (acepifylline), bamifylline and the like.

      In addition, there is a mucus solubilizer or expectorant that dissolves the produced mucus to reduce viscosity and promote bronchial cilia, thereby promoting sputum discharge. Airway mucus has several important functions in prayer. That is, it protects the airway from particles entering the airway from the outside, maintains the humidity of the intake air, and serves to remove the inhaled chemicals and gases by binding to the mucus protein, cilia. Mucus also has substances that play an important role in immune function, such as immunoglobulin A (IgA), lysozyme, lactoferrin, and the like. Most expectorants have been used as folk medicines or experience prescriptions for thousands of years using plants, etc. Compounds include cysteine derivatives such as carbocysteine, N-acetylcysteine, and cysteine ethyl ester hydrochloride. It is used as an expectorant. The above-mentioned cysteine derivatives are not completely satisfactory when used as an expectorant, and in particular, N-acetyl cysteine and cysteine ethyl ester hydrochloride have both high toxicity and chemical instability. Therefore, the development of expectorants with good physical and chemical stability and less side effects, toxicity and good expectorant effects has been required.

Recently, researches on antitussive expectorants derived from natural products have been actively conducted. In this regard, representative studies related to airway stimulate the vagus nerve of the airway to promote the secretion of mucous membranes to express expectoration and at the same time play an auxiliary role of antitussive action. There are also reports on plants containing saponins, alkaloids, etc. (Sook Young Kim et al . , Kor. J. Pharmacogn . 19 (2): 133-140, 1998).

      Third, inflammatory mediators are released from mast cells due to physical and chemical factors. Mast cells contain small cytoplasmic granules containing inflammatory mediators such as histamine and cytokines. When exposed to an allergen, the body produces an antibody called IgE in B cells, which attaches to the surface of mast cells. Subsequent exposure to allergens causes the release of allergens, including histamine, a potent inflammatory mediator, from IgE-attached mast cells, resulting in increased secretions in the airways, effusions from inflammation, inhaled foreign bodies, and bacteria. Leads to. Existing drugs such as codeine, widely used as antitussives, have excellent sedative effects on breathing and coughing, but have side effects that release histamine by causing degranulation of mast cells.

  In addition, based on the above description, the mechanism and function closely related to antitussive expectoration, antibacterial action to enable the removal of the causative agent and prevention of secondary infection, anti-inflammatory action to inhibit the synthesis of inflammatory mediators, histamine from mast cells Antihistamine activity that inhibits secretion, antioxidant activity that prevents inflammation and tissue damage, elastase activity release that releases inflammatory mediators from immune cells, hyaluronidase activity involved in vascular permeable inflammatory reactions Inhibition, etc. will be a function that requires.

 Therefore, the present inventors have studied to develop an expectorant or antitussive composition, the present invention by confirming that the mixture of the sole herbal extract of baekbaek, rare or yeongyo and the extract of the sole herbal extract shows expectorant activity, antitussive activity and antihistamine activity effect Was completed.

In order to accomplish the above object, the present invention provides an expectorant or antitussive composition containing one or more extracts selected from the group consisting of yellowish white, rare and yeonkyo as an active ingredient.

      In addition, the present invention contains two or more mixed herbal extracts selected from the group consisting of yellowish white, rare and yeongyo as an active ingredient, the mixed herbal extract is a mixture of yellowish white extract, raree extract and / or ductile extract, expectorant or Jinhae It provides a composition for.

   Herbal medicine (Phellodendri cortex) used in the present invention is a perennial herb belonging to the family Rutaceae. The bark of yellow wall and related plants is called yellow white. The outside is grayish brown to gray brown and the inside is yellow to dark yellowish brown. It is known that baekbaek has pharmacological effects such as antibacterial action, hypoglycemic action, anti-inflammatory and anti-cancer action, and is used in herbal medicine as a gastric agent, diuretic agent, anti-inflammatory agent, and subcutaneous bleeding absorption accelerator. Main pharmacological ingredients include alkaloids such as berebrine, palmatine, copmatine, coptisine, jatrorrhizine, phellodendrine, magnoflorine, etc. It is known to have been (Jung Ji-sup, Shin Min-kyo, Doha Herbal Dictionary), 790-791, 1990.

Herbal medicine (Siegesbeckiae Herba), which is used in the present invention, is an annual herb belonging to the genus Compositae and is the ground part of Siegebeckia pubescens Makino, Siegebeckia glabrescens Makino, and the related plant. The height is usually 50-100cm, the stem is upright, and usually purple. Rhubarb is known to have pharmacological effects such as anti-inflammatory action, hypotensive action, anti-inflammatory and anti-cancer action, and in traditional medicine, for the purpose of treating limb paralysis, arthralgia and myalgia, malaria, acute hepatitis, hypertension and traumatic bleeding. Has been used. The main ingredients so far known are alkaloids such as darutin, chilenol, esters such as 17-hydroxy-16alpha (-)-kauran-19-carboxylic acid, 16-acetyl- Diterpenes such as chilenol, darutizenol, darutoside, isopropylidenechilenol, chilenol, neodarutoside, sisesvecchiol and siesesvecchioside are known (1. , Shin Mingyo, Dohae Hyangje (Medicinal Medicine), 1070-1071, 1990., 2. Chinese Medicinal Dictionary, Book Publishing Jungdam, 6660-6666, 1998).

    Herbal medicine (Forsythiae Fructus), which is used in the present invention, belongs to Oleaceae and is a fruit of forsythia and related plant. It is a deciduous shrub reaching about 3m in height, with branches extending sideways or extending long and sagging like vines. Yeongyo is known to have pharmacological effects such as antibacterial action, antiviral action, cardiovascular action and diuretic effect, and has been used in Chinese medicine for treatment of swelling, gonorrhea, pain, hemorrhoids, diuresis, tuberculosis, and detoxification. The major ingredients known to date are known to contain Forsythol, sterol compounds, saponins, flavonol glycosides, oleanolic acid and alkaloids (1. -975, 1990., 2.Kim TJ.Korean Resources Plants, 262, Seoul National University Pub. 1991).

      Investigation of the results of respiratory diseases for each of the white and yellow extracts and the extracts showed that respiratory diseases were related to respiratory diseases, more specifically airway contraction inhibitory activity, airway inflammation inhibitory effect, and 5-lipoxygenase inhibition. Patent application for asthma-related diseases such as activity, phosphodiesterase 4 inhibitory activity, leukotriene D4 antagonism, antihistamine activity, but related to expectorant and antitussive activity It has not been studied yet.

      Therefore, the difference between the expectorant and antitussive activity of the present invention and conventional asthma is explained as follows.

      Asthma is a chronic noncommunicable obstructive airway disease in which the bronchus responds to various stimuli. When the airways are subjected to extensive irritation such as inflammatory reactions and mucosal edema, the airway smooth muscles contract excessively, and asthma attacks, which are mainly caused by airway obstruction, occur. The pathogenesis of asthma is when TH2 cells are activated when antigen from the outside enters the body to secrete cytokines such as interleukin-4 and interleukin-5, and these cytokines differentiate B cells into plasma cells to produce IgE antibodies. Promotes production and mast cell proliferation. The produced IgE binds to the mast cell's IgE receptor, and when the antigen enters the body secondly, an antigen-antibody reaction occurs to secrete an inflammatory mediator such as histamine, causing bronchial contraction. Mechanisms for treating asthma include anti-inflammatory drugs aimed at reducing bronchial inflammation, drugs that inhibit degranulation of mast cells, leukotriene pathway-controlling drugs that cause allergies or inflammation, and drugs that have bronchodilator effects. Can be distinguished. In the case of Rareul used in the Korean Patent Laid-Open Publications, symptomatic activity and 5-lipoxygenase inhibitory activity, phosphodiesterase 4, such as airway contraction suppression experiments and airway inflammation suppression experiments associated with the above pharmacological basis and mechanism of action The use for anti-asthma activity is described on the basis of mechanism-specific inhibitory activity against inhibitory activity, leukotriene D4 antagonism and antihistamine action.

      On the other hand, the mechanism of action and symptoms of antitussive expectorant activity according to the present invention is distinguished from asthma. That is, cough occurs through cough reflexes. When the cough receptors are exposed to physical stimuli or chemical stimuli by various chemicals, they are passed through afferent channels such as the vagus nerve and the trigeminal nerve. Is passed on. The delivered stimulus is processed through the process of integration and transformation at the cough center and then through the centrifugal channels such as the vagus nerve, the diaphragm nerve, and the spinal motor nerve.

      In addition, these various cough irritants activate coughs by activating various receptors in the airways. Cough receptors are distributed in various parts of the human body, mainly in the larynx or bronchus, and are mainly stimulated through the vagus nerve. Sensory nerve endings in cough consist of a variety of receptors such as C-fibers, Aδ-fibers, rapidly adapting receptors (RARs), and slowly adapting stretch receptors (SARs). (Drug Discovery Today: Disease Models vol. 1, No. 3, 2004, p. 297-302).

      Therefore, central cough and peripheral cough suppressants that suppress cough central and cough sensory nerves are mainly used to control cough. Central cough suppresses cough reflexes by directly acting on the cough centers of the softened areas of the brain. Peripheral antitussives are known to control cough by blocking or inhibiting the activity of cilia that cause cough (Pulmonary Pharmacology (1996) 9, 357-364).

     The expectorant activity inhibits the production of sputum in the bronchi due to the inflow of dust or irritants, or promotes the release of sputum, and the mechanism varies depending on the drug. It acts directly on mucous membranes to stimulate sputum secretion or reflexively through the vagus nerve to facilitate removal of irritants from the lower bronchus into the pharynx, and also to alter or break down the binding of viscous protein molecules in sputum. It may also be used to dilute the viscosity of viscosities, to promote the production of surfactants, to dissolve bronchial secretions, to promote mucus secretion, and to promote bronchial cilia, thereby increasing the rate of discharge of dissolved sputum. , Eun Jong-eun et al., Hyeonmunsa, 2005, p. 334-336).

      In the present invention, through the experiment to verify the activity to suppress the cough symptoms and sputum symptoms using the most widely used animal model, it was confirmed that the composition used in the present invention exhibits antitussive and expectorant activity. The experimental model for cough suppression ability performed in the present invention is the most widely used method for the evaluation of antitussives, and the guinea pigs used in the experiment are also usefully used as the most suitable animal model for cough research. In addition, since the reaction in the guinea pigs to citric acid used in the present invention is similar to that in humans, guinea pigs are also a good model for studying human cough reflexes (Drug Discovery Today: Disease Models, Vol. 3, No. 3, 2006, p. 237-241).

      The phenol red excretion test performed in the present invention was also designed as a method for assaying bronchial mucus secretion ability, and in fact, many drugs widely known as effective expectorants were verified using this method, and thus excellent in verifying expectoration activity. It is known to be an animal model (Journal of Pharmacological Methods 11, 1984, p. 151-157).

     Therefore, the cough of the present invention describes a neurostimulating cough that is distinguished from an allergic cough appearing in asthma. As described above, the antitussive and expectorant activity of the present invention is completely different from the asthma in its pathogenesis. The present invention relates to a composition useful for the treatment of antitussive expectoration, which completes the present invention by demonstrating that antitussive and expectorant activity is excellent by a scientifically suitable evaluation method.

      In the present invention, the term 'mixed extract of yellow white, rare and / or duct bridges' refers to a mixture of yellow white extract, rare extract and / or duct extract, which is obtained by extracting yellow white, rare and duct bridges respectively, and yellow white, rare and / or duct extract. Or it is used to mean all the extracts obtained by extracting a mixture of duct bridge. In addition, the 'extract' refers to a crude extract or a specific solvent soluble extract (fraction), and may be in a solution, concentrate or powder state.

      "Extract" as defined herein is characterized in that the crude extract of the crude drug or a polar solvent soluble extract of the crude extract.

      The crude extract as defined herein is a solvent selected from water, including purified water, straight-chain or branched alcohols having 1 to 6 carbon atoms or mixed solvents thereof, preferably water, 10-70% (v / v) aqueous ethanol solution or water. It is characterized by a saturated butyl alcohol.

      The polar solvent soluble extract as defined herein is characterized by being a straight or branched alcohol having 1 to 6 carbon atoms, preferably saturated butyl alcohol.

      Hereinafter, the crude extract of the present invention and the method for obtaining the polar solvent soluble extract of the crude extract will be described in detail.

      The yellowish white, rare and softened crude extracts of the present invention are cut into each dried herbal medicine by about 3 to 20 times the weight (g), preferably about 5 to 15 times the water, C1 to C6 straight chain or Branched alcohols or mixed solvents thereof, preferably water, 10 to 70% (v / v) aqueous ethanol solution or saturated butyl alcohol, extraction temperature of 40 ° C to 110 ° C, preferably 55 ° C to 90 ° C The crude extract of the present invention may be obtained by filtration, concentration under reduced pressure, or drying the extract obtained by using a cold, hot water extraction, ultrasonic extraction, reflux cooling extraction method for about 0.5 to 20 hours, preferably about 1 to 10 hours. Can be.

      The crude extract was filtered to collect the filtrate, and then 4 to 7 times the weight of the crude raw material, water or alcoholic solution or saturated butyl alcohol was added to the residue, followed by heating and re-extracting for 2 to 5 hours, followed by filtration and mixing with the previous filtrate. Increase the extraction efficiency If the amount of solvent is too small, the stirring becomes difficult and the solubility of the extract is low, the extraction efficiency is lowered. If the amount is too large, the amount of lower alcohol used in the next purification step is increased, which is not economical and may cause handling problems. . In the present invention, after the first extraction, the method of re-extraction is adopted again. However, even if the medicinal herb extract is mass-produced, even though the filtration is effective, the loss occurs because the water content of the herb itself is high. This is to prevent this. In addition, as a result of verifying the extraction efficiency of each step, it was found that about 80 to 90% of the total extraction amount is extracted by the second extraction, and the third or more multistage extraction is not economical.

      In addition, the polar solvent soluble extract of the present invention is suspended in the crude extract of about 2 to 10 times, preferably about 3 to 7 times the volume of water, the polar solvent such as saturated butyl alcohol 0.5 to 3 times of the suspension, It is preferably prepared by adding the same amount to 2 times, extracting the polar solvent soluble layer for 1 to 5 times, more preferably 2 to 3 times, and then concentrating under reduced pressure.

      The lower alcohol fraction obtained after layer separation is concentrated under reduced pressure at 50-60 ° C. to remove the solvent remaining in the sample. The concentrate thus obtained is azeotropically concentrated two to three times with water of 25 to 50 times the total amount of the concentrate, followed by the addition of the same amount of water and suspended homogeneously. The reason for azeotropic concentration with water at the time of concentrated drying is to effectively control the content of the remaining lower alcohol in order to use the obtained herbal extract as a raw material for pharmaceuticals.

As described above, the extract obtained by extraction with water, C1 to C6 straight chain or branched alcohol, or a mixed solvent thereof is filtered and concentrated, and then impurities such as unnecessary proteins, polysaccharides and fatty acids contained in the filtrate. In the present invention, in the present invention, impurities are purified by performing two to four separations with a filtrate and the same amount of lower alcohol to obtain a solvent fraction. In this case, as the lower alcohol, alcohol having 1 to 6 carbon atoms, preferably butyl alcohol, propyl alcohol or isopropyl alcohol, and when the amount of lower alcohol is less than that of the filtrate, fine particles are formed by unnecessary components such as fatty acids. Therefore, the separation of the layers is not smooth and the extraction content of the active ingredient is lowered, which is not efficient.

The content ratio in the mixed extract may be represented by the following composition.

     The weight ratio of the white and yellow extracts is 10: 1 to 1: 1 based on the solids weight (the weight of the white and yellow extracts), and the weight ratio of the white and yellow extracts is 15: 1 to 1: 1 based on the solids weight. Yellow baek extract weight: duct bridge extract weight), the weight ratio of the rare extract and duct bridge extract is 20: 1 to 1: 1 (rare extract weight: duct extract weight) based on the solid content weight, The weight ratio is preferably 20: 1: 1 to 1: 1: 1 (yellow white extract weight: rare extract weight: duct bridge extract) based on the solid content weight. The term 'solid content' means a state in which the solvent used to prepare the extract is removed, and is the same below.

     In addition, in the mixed polar solvent soluble extract according to one embodiment of the present invention, the content ratio of each extract may be as follows.

     The weight ratio of the white and yellow extracts is 7: 1 to 1: 1 (the weight of the white and yellow extracts) based on the solids weight, and the weight ratio of the white and yellow extracts is 10: 1 to 1: 1 (based on the weight of the solids) Yellow white extract weight: weight of duct bridge extract), the weight ratio of rare extract and duct bridge extract is 10: 1 to 1 (weight of rare extract: weight of duct extract) based on the weight of solids, and weight ratio of baekbaek extract, rare extract and duct bridge extract May be 10: 1: 1 to 1: 1: 1 (yellow white extract weight: rare extract weight: duct bridge extract) based on the solid content weight. As described above, 'solid content' means a state in which the solvent used to prepare the extract is removed.

      The present invention provides a composition for the prevention or treatment of respiratory diseases, containing as an active ingredient one or more herbal extracts selected from the group consisting of yellowish white, rare and yeongyo obtained by the above method.

      In another aspect, the present invention provides a composition for the prevention or treatment of respiratory diseases comprising two or more mixed herbal extracts selected from the group consisting of yellowish white, rare and duct bridge obtained by the production method as an active ingredient.

     Respiratory diseases defined herein include emphysema, chronic bronchitis, bronchial adenoma, isolated pulmonary nodules, pulmonary tuberculosis, empyema, lung abscess, cold, flu or histiocytosis of the lungs, preferably emphysema, pneumonia, cold Contains the flu.

      The composition for preventing and treating a respiratory disease of the present invention comprises 0.001 to 99% by weight, preferably 0.1 to 50% by weight of the compound, based on the total weight of the composition.

      However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.

      The composition comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

      Compositions comprising extracts according to the invention are formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectables, respectively, according to conventional methods. The carriers, excipients and diluents which may be used in the composition comprising the extract, and lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

      Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the time of administration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 1 mg / kg to 1000 mg / kg, preferably 50 mg / kg to 500 mg / kg, more preferably 150 mg / kg to 300 mg / kg per day. The administration may be carried out once a day or divided into several doses. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.

      The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

      The present invention provides a health functional food for the prevention or improvement of respiratory diseases containing at least one herbal extract selected from the group consisting of yellowish white, rare and yeonkyo as an active ingredient.

      In another aspect, the present invention provides a health functional food for the prevention or improvement of respiratory diseases containing two or more mixed herbal extracts selected from the group consisting of yellow white, rare and yeongyo as an active ingredient.

      The composition containing the extract of the present invention can be used in various ways, such as drugs, foods and drinks for the prevention and improvement of respiratory diseases. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamin complexes, health supplements and the like, and they can be used as powders, granules, tablets, capsules or beverages have.

      Since the extract itself of the present invention has little toxicity and side effects, it is a drug that can be used safely even when taken for long periods of time.

      The extract of the present invention may be added to food or beverage for the purpose of preventing and improving respiratory diseases. At this time, the amount of the extract in the food or beverage can be generally added to 0.01 to 15% by weight of the total food weight as a health food composition of the present invention, 0.02 to 10g, preferably 0.3 to about 100ml as a health beverage composition It can be added at a rate of 1 g.

      In addition to containing the extract as an essential ingredient in the indicated ratio, the health beverage composition of the present invention is not particularly limited in the liquid component and may contain various flavors or natural carbohydrates as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include conventional sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol, erythritol and the like. It is a sugar alcohol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

      In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

 The composition for the prevention and treatment of the antitussive and expectorant respiratory disease of the present invention is one or more herbal extracts selected from the group consisting of yellowish white, rare and ducts and two or more mixed herbs selected from the group consisting of yellowish white, rare and ducts By containing the extract as an active ingredient, confirming the expectorant activity, antitussive activity and antihistamine activity, it can be usefully used as a pharmaceutical composition and health functional food useful for the prevention and treatment of respiratory diseases.

  The composition for the prevention and treatment of respiratory disorders showing antitussive and expectorant activity of the present invention is one or more herbal extracts selected from the group consisting of yellowish white, rare and ducts, and two or more mixed herbal extracts selected from the group consisting of yellowish white, rare and ducts It can be usefully used as a pharmaceutical composition and health functional food useful for the prevention and treatment of respiratory diseases by containing as an active ingredient, confirming that the expectorant activity, antitussive activity and antihistamine activity.

Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.

      However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Experimental Examples.

Example 1 Preparation of Single Herbal Crude Extract (A)

1-1. Yellow White Extract (PC-GA)

      After washing the sulfur white purchased from Gyeongdong market with water to remove contaminants, 250 g of the dried sulfur white was extracted with 2.0 L of water, 50% ethanol aqueous solution and saturated butanol twice at 80 ° C. for 3 hours and then extracted with hot water. After filtration and concentration under reduced pressure, 52.5 g (21.0% yield of the original drug), 45.0 g (18.0% yield) and 25.5 g (10.2% yield of the original drug) of the extract were obtained. , PC-GA-2 and PC-GA-3 were used as experimental examples, and PC-GA-1 and PC-GA-2 were used as samples in Example 2-1.

1-2. Rare Extract (SH-GA)

      After removing rare substances by washing with rare water purchased from Gyeongdong market, 250 g of dried rare water was extracted with 2.0 L of water, 50% ethanol aqueous solution and saturated butanol twice at 80 ° C. for 3 hours, and then extracted with extract. After filtration and concentration under reduced pressure, extracts 49.0 g (19.6% yield) and 42.0 g (16.8% yield) and 21.0 g (8.4% yield) were obtained. , SH-GA-2 and SH-GA-3 were used as experimental examples, of which SH-GA-1 and SH-GA-2 were used as samples in Example 2-2.

1-3. Yeongyo Extract (FS-GA)

      After removing the contaminants by washing the bridges purchased at Gyeongdong Market with water, 250 g of the dried bridges were extracted with 2.0 L of water, 50% ethanol solution and saturated butanol, and extracted twice with hot water at 80 ° C. for 3 hours. After filtration and concentration under reduced pressure, 52.5 g (21.0% yield of the original drug), 46.7 g (18.7% yield of the original drug) and 18.4 g (7.4% yield of the original drug) were obtained, respectively, FS-GA- 1, FS-GA-2, named FS-GA-3 was used as an experimental example, of which FS-GA-1 and FS-GA-2 was used as a sample of Example 2-3 below.

Example 2 Preparation of Polar Solvent Soluble Extract of Single Herb Crude Extract (B)

2-1. Yellow White Polar Solvent Soluble Extract (PC-GB)

      To 52.5 g and 45.0 g of PC-GA-1 and PC-GA-2 obtained in Example 1-1, 0.3 L of water was added and suspended, 0.6 L of saturated butyl alcohol was added thereto, and the layers were separated twice. Thereafter, only the saturated butyl alcohol fractions were collected and concentrated under reduced pressure until drying. After most of the butyl alcohol and water were evaporated, 0.2 L of water was added to azeotropically concentrated, and then repeated twice. Finally, 0.1 L of distilled water was added and suspended, followed by lyophilization. (5.1% yield compared to the original drug) and 21.5 g (8.6% yield compared to the original drug) were obtained, which were hereinafter referred to as PC-GB-1 and PC-GB-2, and used as a sample of the following experimental example.

2-2. Rare Polar Solvent Soluble Extract (SH-GB)

      0.3 L of water was added to 49.0 g of SH-GA-1 and 42.0 g of SH-GA-1 and SH-GA-2 obtained in Example 1-2, and 0.6 L of saturated butyl alcohol was added thereto to separate the layers twice. Thereafter, only the saturated butyl alcohol fractions were collected and concentrated under reduced pressure until drying. Most of the butyl alcohol and water were evaporated and azeotropically concentrated by adding 0.2 L of water, and then repeated twice. Finally, 0.1 L of distilled water was added and suspended, followed by lyophilization and 9.3 g of powdered rare extract. (3.7% yield relative to the crude drug) and 15.0 g (6.0% yield relative to the crude drug) were obtained, which were named SH-GB-1 and SH-GB-2 below, and used as a sample of the following experimental example.

2-3. Soft-bridge Polar Solvent Soluble Extract (FS-GB)

      0.3 L of water was added and suspended in 52.5 g and 46.7 g of FS-GA-1 and FS-GA-2 obtained in Example 1-2, and 0.6 L of saturated butyl alcohol was added thereto to separate the layers twice. Thereafter, only the saturated butyl alcohol fractions were collected and concentrated under reduced pressure until drying. Most of the butyl alcohol and water was evaporated, 0.2 L of water was added, the azeotropic concentration was repeated, and then repeated twice. Finally, 0.1 L of distilled water was added and suspended, followed by freeze-drying. (5.3% yield compared to the original drug) and 21.0 g (8.4% yield compared to the original drug) were obtained, hereinafter referred to as FS-GB-1 and FS-GB-2, and used as a sample of the following experimental example.

Example 3: Preparation of a mixture of herbal extracts

The expectorant activity, antitussive activity, and antihistamine activity of the extracts of Examples 1 and 2 were measured, and as shown in Experimental Examples 1 to 6 below, 50% aqueous ethanol solution and the polar solvent resulting therefrom The activity of the soluble extract was excellent and based on this, a mixture was prepared in each combination.

Preparation Example 1 Preparation of Mixture of Yellowish White and Rare Herb Extract

      The mixing ratio of the yellowish white extract (PC-GA-2) of Example 1-1 and the rare extract (SH-GA-2) of Example 1-2 was mixed in a weight ratio of 10: 1 to 1: 1. In order to achieve a homogeneous mixture, 2-3 weight times of water was added to the mixed extract, concentrated under reduced pressure at a temperature of 50 to 60 ° C., and the same amount of water was added to the obtained concentrate, and then suspended. The powder mixture was prepared by lyophilization.

Preparation Example 2 Preparation of Mixture of Yellowish White and Yeonkyo Herbal Medicine Extract

      Mixing the mixing ratio of the sulfur white extract (PC-GA-2) of Example 1-1 and the duct extract (FS-GA-2) of Example 1-3 to 15: 1 to 1: 1 by weight Except that, a mixture was prepared in the same manner as in Preparation Example 1.

Preparation Example 3 Preparation of Mixture of Rare and Yeonkyo Herbal Medicine Extracts

      Mixing the mixing ratio of the rare extract (SH-GA-2) of Example 1-2 and the duct extract (FS-GA-2) of Example 1-3 in 20: 1 to 1: 1 by weight Except that, a mixture was prepared in the same manner as in Preparation Example 1.

Preparation Example 4 Preparation of Mixture of Yellowish White, Rare and Fructus Herbal Extracts

      Mixing of the sulfur white extract (PC-GA-2) of Example 1-1, the rare extract (SH-GA-2) of Example 1-2 and the duct extract (FS-GA-2) of Example 1-3 A mixture was prepared in the same manner as in Preparation Example 1, except that the ratio was mixed from 20: 1: 1 to 1: 1: 1 by weight.

Preparation Example 5 Preparation of Mixture of Soluble White and Rare Polar Solvent Soluble Extracts

      Mixing the mixing ratio of the sulfur white extract (PC-GB-2) of Example 2-1 and the rare extract (SH-GB-2) of Example 2-2 by 7: 1 to 1: 1 by weight Except that, a mixture was prepared in the same manner as in Preparation Example 1.

Preparation Example 6 Preparation of a Mixture of Soluble Extracts of Yellow and Soft Polar Solvents

      Mixing the mixing ratio of the sulfur white extract (PC-GB-2) of Example 2-1 and the duct extract (FS-GB-2) of Example 2-3 in 10: 1 to 1: 1 by weight Except that, a mixture was prepared in the same manner as in Preparation Example 1.

Preparation Example 7 Preparation of Mixture of Soluble Extracts of Lean and Ductile Polar Solvents

      Mixing the mixing ratio of the rare extract (SH-GB-2) of Example 2-2 and the duct extract (FS-GB-2) of Example 2-3 in 10: 1 to 1: 1 by weight Except that, a mixture was prepared in the same manner as in Preparation Example 1.

Preparation Example 8 Preparation of Mixture of Soluble Extract of Yellow White, Rare, and Soft Bridge Polar Solvent

      Mixing of the sulfur white extract of Example 2-1 (PC-GB-2), the rare extract of Example 2-2 (SH-GB-2) and the duct extract of Example 2-3 (FS-GB-2) A mixture was prepared in the same manner as in Preparation Example 1, except that the ratio was mixed from 10: 1: 1 to 1: 1: 1 by weight.

Experimental Example 1: Measurement of expectorant activity of single herbal extract

      In order to measure the expectorant activity of the yellowish white, rare and duct crude crude extracts and the polar solvent soluble extracts of Examples 1 and 2, Engler et al. (Engler H, Szelenyi I, J. Pharmacol. Moth. 11, 151-157, 1984., Bao-quin Lin et., Pulmonary Pharmacology & Therapeutics 21, 259-263, 2008.), experiments were carried out by the following process.

      30 minutes after oral administration of a positive control drug (ambroxol, Sigma) and a test drug (crude extract of Examples 1 to 2 and a polar solvent soluble extract), phenol red was intraperitoneally injected (500 mg / kg dose) Phenol red is dissolved in saline solution). After 30 minutes, anesthetized with diethyl ether, the abdominal aorta was cut and bled, and then the entire trachea was excised. The separated organs were placed in 1 ml of physiological saline, washed for 30 minutes, centrifuged at 10,000 rpm for 5 minutes at room temperature, and 1N caustic soda (NaOH) was added to the supernatant (0.1 ml of 1N NaOH per 1 ml of supernatant). After measuring the absorbance at 546 nm was measured the expectorant activity as a concentration of phenol red, the results are shown in Table 1 below.

               division  Dosage (mg / kg) Sputum discharge capacity (%) Example 1 PC-GA-1 500 39 PC-GA-2 500 47 PC-GA-3 500 45 SH-GA-1 500 32 SH-GA-2 500 43 SH-GA-3 500 40 FS-GA-1 500 27 FS-GA-2 500 36 FS-GA-3 500 37 Example 2 PC-GB-1 500 44 PC-GB-2 500 56 SH-GB-1 500 39 SH-GB-2 500 47 FS-GB-1 500 31 FS-GB-2 500 39  Positive control group (Ambroxol) 250 34

As a result, as shown in Table 1, it was found that the overall activity is excellent, in particular, it was confirmed that the sputum discharge capacity of the PC-GB-2 of Example 2 shows the most excellent activity.

Experimental Example 2. Determination of expectorant activity on a mixture of single herbal extracts

The expectorant activity of each of the extracts of Examples 1 and 2 was measured to find that 50% aqueous ethanol solution (PC-GA-2, SH-GA-2, FS-GA-2) and the resulting polar solvent soluble The activity of the extracts (PC-GB-2, SH-GB-2, FS-GB-2) was excellent and based on this, a mixture was prepared as in Example 3 (Preparation Examples 1 to 8), and The expectorant activity was measured by the method and the results are shown in Table 2 below.

             division Dosage (mg / kg) Sputum discharge capacity (%) Preparation Example 1 10: 1 500 46 3: 1 500 56 1: 1 500 50 Production Example 2 15: 1 500 43 5: 1 500 55 1: 1 500 47 Production Example 3 20: 1 500 44 5: 1 500 52 1: 1 500 39 Preparation Example 4 20: 1: 1 500 48 3: 1: 1 500 59 1: 1: 1 500 51 Preparation Example 5 7: 1 500 46 3: 1 500 58 1: 1 500 48 Preparation Example 6 10: 1 500 46 3: 1 500 52 1: 1 500 43 Preparation Example 7 10: 1 500 43 3: 1 500 49 1: 1 500 39 Preparation Example 8 10: 1: 1 500 50 3: 1: 1 500 64 1: 1: 1 500 52  Positive control group (Ambroxol) 250 32

  As a result of the experiment, as shown in Table 2, when the mixture was prepared, it was confirmed that the effect is increased than when the extract alone, in particular, it was confirmed that the sputum discharge ability showed the most excellent activity when mixing three herbal drugs .

Experimental Example 3. Determination of antitussive activity of single herbal extract

      In order to measure the antitussive activity of the yellowish white, rare and duct crude crude extracts and the polar solvent soluble extracts of Examples 1 to 2, using Tanaka et al. (Motomu Tanaka and Kei Maruyama., J. Pharmacol. Sci. 93, 465-470, 2003., Daoui, Cognon, Naline et., Am. J. Respir. Crit.Care.Med. 158, 42-48, 1998.), experiments were carried out as follows.

      After 1 hour of oral administration of test drug to male guinea pigs (6 weeks old, Samtaco Bio Korea), the guinea pigs were placed in a plastismograph chamber (Buxco, USA), and then sprayed with citrate-citing citric acid (Sigma). Causing a cough. As a positive control, theobromine (Sigma), which is used as an antitussive agent, was used. The guinea pig was exposed to 2 M citric acid for 10 minutes, and the cough water generated at this time was measured for 15 minutes, and the results are shown in Table 3 below.

                 division Dosage (mg / kg) Cough suppression ability (%) Example 1 PC-GA-1 200 39 PC-GA-2 200 50 PC-GA-3 200 48 SH-GA-1 200 37 SH-GA-2 200 48 SH-GA-3 200 45 FS-GA-1 200 35 FS-GA-2 200 43 FS-GA-3 200 40 Example 2 PC-GB-1 200 45 PC-GB-2 200 58 SH-GB-1 200 43 SH-GB-2 200 55 FS-GB-1 200 40 FS-GB-2 200 52     Theobromine 50 58

Experimental Example 4. Determination of antitussive activity against a mixture of single herbal extracts

The antitussive activity of each of the extracts of Examples 1 and 2 was measured to find that 50% aqueous ethanol solution (PC-GA-2, SH-GA-2, FS-GA-2) and the resulting polar solvent soluble The activity of the extracts (PC-GB-2, SH-GB-2, FS-GB-2) was excellent and based on this, a mixture was prepared as in Example 3 (Preparation Examples 1 to 8) to the method of Experimental Example 3 Antitussive activity was measured and the results are shown in Table 4 below.

division Dosage (mg / kg) Cough suppression ability (%) Preparation Example 1 10: 1 200 47 3: 1 200 60 1: 1 200 55 Production Example 2 15: 1 200 49 5: 1 200 56 1: 1 200 50 Production Example 3 20: 1 200 45 5: 1 200 53 1: 1 200 48 Preparation Example 4 20: 1: 1 200 54 3: 1: 1 200 62 1: 1: 1 200 58 Preparation Example 5 7: 1 200 49 3: 1 200 61 1: 1 200 48 Preparation Example 6 10: 1 200 53 3: 1 200 59 1: 1 200 52 Preparation Example 7 10: 1 200 54 3: 1 200 59 1: 1 200 54 Preparation Example 8 10: 1: 1 200 58 3: 1: 1 200 68 1: 1: 1 200 61   Positive control group (Theobromine) 50 58

As a result of the experiment, as shown in Table 4, when the mixture was prepared, it was confirmed that the effect is increased than when the extract alone, in particular, it was confirmed that the cough inhibitory activity showed the most excellent activity when mixing three herbal drugs .

Experimental Example 5. Determination of antihistamine activity of single herbal extract

      In order to measure the antihistamine activity of the yellowish white and ductile crude extract and the polar solvent soluble extract of Examples 1 to 2, using a method such as Honuchi (Masako Honuchi and Yoshiyuki Seyama, J. Health Sci., 52 (6 ), 711-717, 2006., Naoki Inagaki et. Biol. Pharm. Bull. 24 (7), 829-834, 2001.

      Antihistamine effects were measured using celiac cells of male rats (7 weeks old, Samtaco Bio Korea) sensitized with egg white albumin. Ketotyfen (Ketotifen, Sigma) was used as a positive control. Rats sensitized with egg white albumin were orally administered with the test drug and orally with the drug for three days, and then the peritoneal mast cells were isolated. Isolated celiac mast cells (2 × 10 5 cells / ml) were again treated with the drug. Finally, compound 48/80 (compound 48/80, Sigma), a substance that induces degranulation of mast cells to secrete histamine by the non-immunological method, is treated in the same concentration at a concentration of 10 μg / ml. The amount of free histamine was quantified to determine whether the test substances inhibited histamine release from mast cells. Relative amounts relative to the amount of histamine released from mast cells in rats that were not administered any drug were measured, and the results are shown in Table 5 below.

      division Oral Dose (mg / kg) Mast Cell Concentration (mg / ml) Histamine Release Rate (%)     Example 1 PC-GA-1 200 0 44 0.1 39 1.0 31 10.0 28 200 0 40 PC-GA-2 0.1 36 1.0 29 10.0 25 PC-GA-3 200 0 42 0.1 37 1.0 30 10.0 26 FS-GA-1 200 0 48 0.1 43 1.0 39 10.0 32 FS-GA-2 200 0 47 0.1 42 1.0 37 10.0 30 FS-GA-3 200 0 49 0.1 45 1.0 39 10.0 34 Example 2
PC-GB-1 200 0 44 0.1 37 1.0 31 10.0 26 PC-GB-2 200 0 41 0.1 33 1.0 28 10.0 22 FS-GB-1 200 0 49 0.1 42 1.0 37 10.0 34 FS-GB-2 200


0 47 0.1 38 1.0 33 10.0 30 Positive control group
(Ketotifen) 5


0 43 0.01 40 0.1 33 1.0 19

Experimental Example 6. Determination of antihistamine activity on a mixture of single herbal extracts

As a result of measuring the antihistamine activity of each extract of Example 1 and Example 2, 50% aqueous ethanol solution (PC-GA-2, FS-GA-2) and the resulting polar solvent soluble extract (PC-GB- 2, FS-GB-2) was excellent and based on this, the mixture was prepared as in Example 3 (Preparation Examples 1 to 8) to measure the antitussive activity by the method of Experimental Example 5 and the results are shown in Table 6 below. It was.

             division Oral Dose (mg / kg) Mast Cell Concentration (mg / ml) Histamine Release Rate (%) Preparation Example 1 10: 1 200 0 44 0.1 37 1.0 28 10.0 23 3: 1 200 0 45 0.1 36 1.0 27 10.0 20 1: 1 200 0 45 0.1 40 1.0 34 10.0 27 Production Example 2 15: 1 200 0 43 0.1 39 1.0 31 10.0 26 5: 1 200 0 42 0.1 32 1.0 26 10.0 21 1: 1 200 0 46 0.1 39 1.0 31 10.0 24 Production Example 3 20: 1 200 0 47 0.1 42 1.0 37 10.0 32 5: 1 200 0 46 0.1 38 1.0 31 10.0 24 1: 1 200 0 46 0.1 40 1.0 33 10.0 28 Preparation Example 4 20: 1: 1 200 0 46 0.1 42 1.0 33 10.0 26 3: 1: 1 200 0 42 0.1 33 1.0 26 10.0 18 1: 1: 1 200 0 46 0.1 38 1.0 32 10.0 23 Preparation Example 5 7: 1 200 0 42 0.1 35 1.0 29 10.0 23 3: 1 200 0 41 0.1 33 1.0 27 10.0 19 1: 1 200 0 43 0.1 36 1.0 29 10.0 20 Preparation Example 6 10: 1 200 0 44 0.1 34 1.0 29 10.0 22 3: 1 200 0 43 0.1 32 1.0 26 10.0 20 1: 1 200 0 46 0.1 37 1.0 29 10.0 22 Preparation Example 7 10: 1 200 0 47 0.1 40 1.0 36 10.0 28 3: 1 200 0 46 0.1 34 1.0 28 10.0 21 1: 1 200 0 47 0.1 39 1.0 32 10.0 27 Preparation Example 8 10: 1: 1 200 0 45 0.1 34 1.0 26 10.0 20 3: 1: 1 200 0 42 0.1 32 1.0 22 10.0 18 1: 1: 1 200


0 46 0.1 39 1.0 29 10.0 21 Positive control group
(Ketotifen) 5

0 43 0.01 39 0.1 33 1.0 20

As a result of the experiment, as shown in Table 6, when the mixture was prepared, it was confirmed that the effect is increased than when the extract alone, in particular, it was confirmed that the most excellent antihistamine activity when mixing the three herbs.

      Hereinafter, the preparation examples of the composition including the extract of the present invention, but the present invention is not intended to limit it, but is intended to explain in detail only.

Formulation Example 1 Preparation of Powder

80 mg of extracts of Examples 1-3

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2 Preparation of Tablet

100 mg of extract of Examples 1 to 3

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

      After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation Example 3 Preparation of Capsule

100 mg of extract of Examples 1 to 3

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

      According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Injection

10 mg extract of Examples 1 to 3

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

Na2HPO4,12H2O 26 mg

      According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation Example 5 Preparation of Liquid

20 mg of extracts of Examples 1 to 3

10 g of isomerized sugar

5 g of mannitol

Purified water quantity

      After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.

Formulation Example 6 Preparation of Healthy Food

1000 mg of extract of Examples 1-3

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

50 μg folic acid

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

      Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Formulation Example 7 Preparation of Healthy Drink

1000 mg of extract of Examples 1 to 3

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

      The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >

      Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (20)

Pharmaceutical composition for antitussive or expectorant containing sulfur extract as an active ingredient. A pharmaceutical composition for antitussive or expectorant containing Yeongyo extract as an active ingredient.  Jinhae or expectorant pharmaceutical composition containing a mixed extract of baekbaek and Yeongyo as an active ingredient.  The method of claim 3, The pharmaceutical composition for antitussive or expectorant of the antitussive or expectorant, wherein the weight ratio of the yellowish white extract and the bristle extract in the mixed extract is 15: 1 to 1: 1 based on the weight of the solid content. A pharmaceutical composition for antitussive or expectorant, containing as a active ingredient a mixed extract of baekbaek, rare and yeonkyo. The method of claim 5, Jinhae or expectorant pharmaceutical composition for which the weight ratio of the yellowish white extract, the rare extract and the duct extract in the mixed extract is 20: 1: 1 to 1: 1: 1 (based on the weight of the solid extract) . The method according to any one of claims 1 to 6, The extract is an antitussive or expectorant pharmaceutical composition, which is an extract available in water and at least one solvent selected from the group consisting of linear or branched alcohols having 1 to 6 carbon atoms. The method of claim 7, wherein The extract is an antitussive or expectorant pharmaceutical composition further comprising water and an extract available in one or more solvents selected from the group consisting of linear or branched alcohols having 1 to 6 carbon atoms. A pharmaceutical composition for the prophylaxis or treatment of respiratory diseases comprising the composition of any one of claims 1 to 6. 10. The method of claim 9, The respiratory disease is emphysema, chronic bronchitis, bronchial adenoma, isolated pulmonary nodules, pulmonary tuberculosis, empyema, pulmonary abscess, cold, flu or histocyte hyperplasia of the lung pharmaceutical composition for the treatment or treatment. 10. The method of claim 9, The composition is a powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, transdermals, suppositories or sterile injectable pharmaceutical composition for the prevention or treatment of respiratory diseases. Health functional food for the prevention or improvement of respiratory diseases comprising the composition of any one of claims 1 to 6. The method of claim 12, A dietary supplement in the form of a powder, granule, tablet, capsule or beverage. delete delete delete delete delete delete delete